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Abstract 
Background: Cognitive function is reported to improve after the initiation of combination antiretroviral therapy 
(cART). Data on the evolution of such changes are limited. We assessed the dynamics of changes in cognitive param‑
eters, in HIV‑positive subjects initiating cART.
Methods: Cognitive function in seven domains was evaluated for HIV‑infected patients without clinically significant 
cognitive impairment prior to the initiation of cART, and 24 and 48 weeks after. Cognitive scores were transformed 
using standardised z‑scores according to the pooled baseline standard deviation. Global, speed, and accuracy com‑
posite z‑scores were calculated with changes calculated using a paired t test.
Results: In 14 subjects, change in global cognitive z‑scores from baseline was by 0.08 at week 24 (p = 0.59) and 0.15 
at week 48 (p = 0.43). Change in composite speed and accuracy z‑scores from baseline at weeks 24/48 were 0.07/0.05 
(p = 0.45/0.82) and 0.13/0.23 (p = 0.47/0.45), respectively. In two of the cognitive domains assessing speed (learn‑
ing and monitoring time), a continued improvement from baseline to weeks 24 and 48 was observed (changes of 
0.06–0.08 and 0.10–0.19, respectively), whereas in two domains (detection and identification) an initial improvement 
at week 24 (changes of −0.10 and 0.04 from baseline, respectively) was followed by a deterioration in score at week 
48 (changes of −0.12 and −0.08 from baseline, respectively). None of these changes were statistically significant.
Conclusions: A trend for improvement in cognitive function was observed in naïve HIV‑positive patients starting 
cART. The dynamics of this improvement differed both between cognitive domains and the time‑points assessed.
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Background
Cognitive impairment is a frequently reported complica-
tion in otherwise effectively treated HIV-positive indi-
viduals [1, 2]. The presence of HIV-associated cognitive 
impairment has been associated with reduced quality of 
life and higher mortality [3, 4].
In general, improvements in cognitive function have 
been reported in patients initiating antiretroviral ther-
apy [5–7]. Data describing the dynamics of changes in 
cognitive function after the initiation of cART are sparse 
[8, 9]. An understanding of the dynamics of these changes 
is crucial to assist in the design of future research pro-
grammes assessing cognitive function within longitu-
dinal cohorts and to assist in diagnostic algorithms for 
cognitive impairment in treated HIV-disease.
The aim of this study was to assess changes in cognitive 
parameters and the dynamics of these changes within 
individual cognitive domains in people living with HIV 
(PLWH) commencing antiretroviral therapy.
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Methods
Study design and procedures
This analysis was undertaken as part of an open-labelled, 
randomised, prospective clinical trial conducted at Impe-
rial College Healthcare NHS Trust (St Mary’s Hospital, 
London, UK) and the Heart of England NHS Foundation 
Trust (Birmingham, UK) between February 2008 and 
October 2012.
Within the study protocol, subjects were randomised 
on a 1:1 basis to emtricitabine (200 mg once daily) + ten-
ofovir disoproxil fumarate (245 mg once daily) plus either 
atazanavir (300 mg once daily) + ritonavir (100 mg once 
daily) or nevirapine 400 mg (once daily).
Subject selection
ART-naïve, HIV-positive patients aged over 18, with no 
clinically overt cognitive impairment or abnormalities on 
screening laboratory testing were eligible to participate. 
In line with national prescribing guidelines for the use 
of nevirapine as an antiretroviral agent, CD4+  lympho-
cyte count <400 cells/μL and <250 cells/μL were required 
for males and females, respectively. Exclusion criteria 
included current history of major psychiatric disorders, 
significant co-morbidities, use of concomitant medica-
tion with potential drug–drug interactions, or evidence 
of HIV-1 genotypic resistance mutations.
This study was registered in the European Clinical Tri-
als Database (EudraCT number 2007-002405-47) and 
national human ethics committee approval was granted 
prior to recruitment. All patients gave informed consent 
before screening.
Cognitive testing
A computerised cognitive test battery (CogState™) [10, 
11] was performed at baseline, weeks 24 and 48. This 
battery comprised of seven tasks and required approxi-
mately 10–15  min to complete. The tasks were in the 
form of card games and specifically assessed the follow-
ing domains: detection, identification, monitoring and 
matched learning (all assessed via speed of test); asso-
ciate learning, one card learning and working memory 
(assessed via accuracy of test). All study participants 
completed one full practise test prior to study examina-
tion to optimize performance at baseline.
Statistical methods
We initially aimed to recruit 40. Given only 14 subjects 
completed our study, this analysis is descriptive with no 
formal comparisons across treatment arms..
All statistical calculations were performed using SPSS 
(version 22.0; SPSS Inc., Chicago, IL, USA) and analysis 
was conducted according to CogState™ recommenda-
tions. Reaction times were log10-transformed because of 
a positive skew of the distribution, and accuracy meas-
ures were transformed using arcsine-root transforma-
tion. For each subject, results were standardized as 
z-scores according to the pooled baseline standard devia-
tion (SD) for each domain.
Composite z-scores were calculated overall (global) and 
for the speed and accuracy domains based on the average 
of standardized z-scores. Changes from baseline scores 
to weeks 24 and 48 were calculated for each individual 
and composite domain. For the calculation of composite 
scores and changes, z-scores involving speed domains 
were multiplied by −1. This transformation allowed for 
all parameters a positive change to represent an improve-
ment in function whereas a negative change from base-
line represented deterioration in function. Statistical 
significance of changes in scores from baseline to weeks 
24 and 48 was assessed for every parameter accordingly 
using a paired t test.




24 subjects were screened, 20 were enrolled and 14 
completed all study procedures. Among those six who 
did not complete study procedures, four dropped out 
and two lacked complete cognitive data. Patient charac-
teristics are summarised in Table  1. Plasma HIV RNA 
was  <50  copies/mL at weeks 36 and 48 (Table  1) in all 
subjects.
Cognitive function changes over 48 weeks
Overall, there were improvements in cognitive function 
over the study period but these changes were not statisti-
cally significant. For instance, global composite changes 
in z-scores (SD) increased from 0.08 (0.54) at week 24 
(p = 0.59) to 0.15 (0.60) at week 48 (p = 0.43) (Table 2). 
Likewise, the changes from baseline in composite accu-
racy speed z-scores (SD) increased from 0.13 (0.63) at 
week 24 to 0.23 (0.93) at week 48. Such improvements 
in z-scores were also observed in the composite speed 
z-scores: 0.07 (0.37) at week 24 and remained stable by 
0.05 (0.67) at week 48.
All three accuracy domains (associate learning, one 
card learning and working memory) showed an improve-
ment from baseline to week 24 (z-score changes of 0.01, 
0.17 and 0.41, respectively). At week 48, such improve-
ments were sustained for one card learning and working 
memory (z-score changes of 0.11 and 0.34 from baseline, 
respectively) and increased for associate learning (z-score 
change of 0.19 from baseline).
Speed domains such as matched learning and monitor-
ing time showed a continued improvement from baseline 
Page 3 of 5Mora‑Peris et al. AIDS Res Ther  (2016) 13:20 
to week 24 and then to week 48 (changes of 0.06 to 0.08 
and 0.10 to 0.19, respectively), whereas others such as 
detection and identification showed an initial improve-
ment at week 24 (changes of 0.10 and 0.04 from base-
line, respectively) followed by a small decline at week 48 
(changes of −0.12 and −0.08 from baseline, respectively) 
(Table 2).
Discussion
We assessed changes in cognitive parameters in HIV-
positive subjects at 24 and 48  weeks after commencing 
cART for the first time.
We observed general trends suggesting an initial 
improvement in composite speed and accuracy cognitive 
domains at week 24, which continued to week 48 after 
starting cART. However, none of these trends were of sta-
tistical significance, which may be due to the small num-
ber of subjects studied.
Previous studies have reported overall neuropsy-
chological function improvement to peak around 
24–36  weeks after cART initiation with these improve-
ments prolonged up to week 48 [6]. Similarly, in the 
ALTAIR study speed and accuracy domains improved 
over the first year after cART initiation with no indi-
vidual domain showing deterioration from baseline at 
week 48 [7]. However, in the long term follow up of this 
study a decline in global cognitive function score was 
observed over 144  weeks and the authors hypothesised 
this could be related to antiretroviral toxicities [12]. In 
our study, domains critically affected in HIV-associated 
cognitive impairment such as detection and identifica-
tion times [13] deteriorated slightly at week 48 after an 
initial improvement at week 24 (Table 2). This highlights 
that different dynamics of change are observed in differ-
ent cognitive domains including potential fluctuations 
over time suggesting that different domains should be 
explored independently as well as a part of global cog-
nitive assessments. Some limitations to consider while 
interpreting these data are the likelihood of a learning 
Table 1 Patient demographics and  clinical characteristics 
throughout the study
a Mean (SD) unless otherwise stated. No statistically significant differences 
(p > 0.1) for any parameters between study arms
Parametera (n=14)
Age (years; range) 37.4 (23–48)
Male, n (%) 14 (100 %)
Ethnicity (%)
 White 9 (64.3 %)
 Black 3 (21.4 %)
 Asian 2 (14.3 %)
Baseline CD4+ count (cells/μL) 280 (129)
Baseline HIV RNA (log copies/μL) 4.42 (0.58)
HIV‑1 clade B, n (%) 10 (71.4 %)
Patients with HIV RNA <50 copies/μL, n (%)
 Week 24 11 (78.6 %)
 Week 36 14 (100 %)
 Week 48 14 (100 %)
Table 2 Changes in Z-score neurocognitive testing param-
eters at weeks 24 and 48 from baseline
All change estimates are based on pooled‑standard‑deviation standardized 
z‑score changes
N number of subjects, SD standard deviation of the change, CI confidence 
interval. Shaded areas, z‑score changes
a Used to determine speed (sp); a positive change in z‑score represents an 
improved response
b Used to determine accuracy (acc) of response; a positive change in z‑score 
represents an improved response
c A positive change in z‑score represents an improved response. Global 
composite = composite accuracy + speed
Cognitive domain Overall
n Z-score change SD of change p value
Detectiona
 W24 14 0.10 0.68 0.59
 W48 12 −0.12 0.79 0.61
Identificationa
 W24 14 0.04 0.75 0.84
 W48 11 −0.08 0.99 0.78
Matched learninga
 W24 14 0.06 0.71 0.76
 W48 11 0.08 0.99 0.78
Monitoring timea
 W24 14 0.10 0.64 0.55
 W48 11 0.19 0.78 0.43
Associate learningb
 W24 13 0.01 0.08 0.65
 W48 10 0.19 0.64 0.36
One card learningb
 W24 14 0.17 1.27 0.62
 W48 12 0.11 1.46 0.78
Working memoryb
 W24 14 0.41 1.00 0.14
 W48 11 0.34 1.30 0.41
Composite speeda
 W24 14 0.07 0.37 0.45
 W48 11 0.05 0.67 0.82
Composite accuracyb
 W24 13 0.13 0.63 0.47
 W48 10 0.23 0.93 0.45
Global compositec
 W24 13 0.08 0.54 0.59
 W48 10 0.15 0.60 0.43
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effect despite a practice neurocognitive test at screening 
and the open-label nature of the study. Additionally, the 
lack of clinically significant cognitive impairment in the 
study population may have reduced the power to detect 
significant improvements. We recruited subjects without 
overt cognitive impairment based on clinical judgement. 
Given we do not have an appropriate control dataset we 
are unable to classify subjects into cognitively impaired 
and non-impaired based on the cognitive testing results 
in our study, which would be of interest after the initia-
tion of cART [8].
We had initially planned to undertake a comparative 
study of two different antiretroviral treatment regimens. 
However, recruitment was challenging. We believe the 
use of nevirapine was one of the factors underlying these 
recruitment difficulties. Firstly, nevirapine was not rec-
ommended as preferred first line treatment for naïve 
patients in the UK by the time the study commenced in 
2008 [14]. Secondly, only patients with low CD4 counts 
(<400  cells/μL and <250  cells/μL for males and females, 
respectively) were eligible to enter this study due to the 
reported increased risk of toxicity for patients with higher 
CD4 counts commencing nevirapine-containing cART 
regimens [14]. This limited the eligible population for our 
study. The HIV-therapeutic field continues to be a rap-
idly changing arena. Recent guidelines changes include 
recommending treatment for all PLWH, irrespective of 
CD4+ lymphocyte count, in view of the results from the 
INSIGHT-START study [15]. Therefore studies stipulat-
ing CD4+ count criteria at entry are no longer feasible or 
ethical. Recent treatment guidelines are swaying towards 
commencing therapy with an integrase-inhibitor contain-
ing regimen [16, 17]. Such changes make recruitment to 
studies using regimens containing non-nucleoside reverse 
transcriptase inhibitors such as efavirenz, which have 
been standard of care for almost a decade, challenging.
In summary, a general trend of improvement in cogni-
tive function parameters was observed in naïve HIV-pos-
itive participants initiating antiretroviral therapy with the 
dynamics of these changes differing between cognitive 
parameters over 48 weeks of follow-up.
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